Related Experiment Video
Updated: Aug 23, 2026

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
Published on: October 18, 2018
Nifedipine and diltiazem suppress ventricular arrhythmogenesis and calcium release in mouse hearts
Richard Balasubramaniam1, Sangeeta Chawla, Lauren Mackenzie
1Physiological Laboratory, University of Cambridge, Downing Street, Cambridge, CB2 3EG, United Kingdom. rnb25@cam.ac.uk
Abstract:
Ventricular arrhythmogenesis leading to sudden cardiac death remains responsible for significant mortality in conditions such as cardiac failure and the long-QT syndrome (LQTS). Arrhythmias may be accentuated by beta-adrenergic stimulation and, accordingly, the present study explored the possible effects of beta-adrenergic stimulation and L-type Ca(2+) channel blockade on ventricular arrhythmogenesis and Ca(2+) handling using the mouse heart as an experimental system. Studies in whole, Langendorff-perfused hearts using programmed electrical stimulation protocols adapted from clinical practice demonstrated sustained ventricular tachycardia following addition of 0.1 microM isoprenaline (n=15), whilst no arrhythmias were observed in the absence of the drug (n=15). Arrhythmias were suppressed by nifedipine or diltiazem pre-treatment (both 1 microM) (n=8 and 4 respectively) and were also induced by elevating external [Ca(2+)] (n=3). At the cellular level, 0.1 microM isoprenaline significantly increased normalized fluorescence (F/F(0)) in field-stimulated fluo-3-loaded mouse ventricular myocytes imaged using confocal microscopy, reflecting increases in sarcoplasmic reticulum Ca(2+) release (n=8). Elevated external [Ca(2+)] also increased F/F(0) (n=4) whilst 0.1 microM nifedipine or 0.1 microM diltiazem significantly decreased F/F(0) (n=13 and 6 respectively). Pre-treatment with 0.1 microM nifedipine or 0.1 microM diltiazem suppressed the increases in F/F(0) induced by 0.1 microM isoprenaline alone (n=14 and 6 respectively). The findings thus paralleled suppression of isoprenaline-induced arrhythmias seen with nifedipine or diltiazem at the whole-heart level. Taken together, the findings may have implications for the use of L-type Ca(2+) channel blockade in conditions associated with beta-adrenergically driven ventricular arrhythmias such as cardiac failure and LQTS.
Insights
Beta-adrenergic stimulation triggers ventricular arrhythmias in mouse hearts. L-type calcium channel blockers like nifedipine and diltiazem effectively suppress these arrhythmias and normalize calcium handling.
Area of Science:
- Cardiovascular Physiology
- Cardiac Electrophysiology
- Pharmacology
Background:
- Ventricular arrhythmias and sudden cardiac death are major concerns in heart failure and long-QT syndrome (LQTS).
- Beta-adrenergic stimulation can exacerbate these arrhythmias.
- L-type calcium channel blockers are used clinically, but their role in modulating beta-adrenergic-driven arrhythmias needs further elucidation.
Purpose of the Study:
- To investigate the effects of beta-adrenergic stimulation and L-type calcium channel blockade on ventricular arrhythmogenesis.
- To examine the impact on intracellular calcium handling in mouse ventricular myocytes.
Main Methods:
- Langendorff-perfused mouse hearts subjected to programmed electrical stimulation.
- Confocal microscopy of fluo-3 loaded ventricular myocytes to assess sarcoplasmic reticulum calcium release.
- Pharmacological interventions included isoprenaline, nifedipine, and diltiazem.
Main Results:
- Isoprenaline induced sustained ventricular tachycardia, which was abolished by nifedipine or diltiazem.
- Isoprenaline increased sarcoplasmic reticulum calcium release, an effect normalized by L-type calcium channel blockers.
- Elevated external calcium also induced arrhythmias and increased calcium release.
Conclusions:
- Beta-adrenergic stimulation promotes ventricular arrhythmias through enhanced calcium release.
- L-type calcium channel blockade effectively suppresses these arrhythmias and normalizes calcium handling.
- Findings suggest a potential therapeutic role for L-type calcium channel blockers in managing beta-adrenergically driven ventricular arrhythmias.

